STX-0119 | 851095-32-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: STX-0119
• 英文别名: N-[5-(2-furyl)-1,3,4-oxadiazol-2-yl]-2-phenyl-4-quinolinecarboxamide；N-[5-(furan-2-yl)-1,3,4-oxadiazol-2-yl]-2-phenylquinoline-4-carboxamide
• CAS: 851095-32-4
• 化学式: C₂₂H₁₄N₄O₃
• 分子量: 382.378
• InChiKey: MNPXTRXFUMGQLK-UHFFFAOYSA-N

物化性质

• 密度：
  1.374±0.06 g/cm3(Predicted)
• 溶解度：
  DMSO: soluble

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  94
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 储存条件：
  2-8°C

制备方法与用途

STX-0119 是一种选择性的口服活性 STAT3 二聚体抑制剂，其 IC50 值为 74 μM，能够有效抑制 STAT3 转录活性。

反应信息

• 作为反应物：
  描述：

  STX-0119 、 碘甲烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 3.0h， 生成 N-[5-(2-furyl)-1,3,4-oxadiazol-2-yl]-N-methyl-2-phenyl-4-quinolinecarboxamide
  参考文献：
  名称：

  STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT

  摘要：

  公开号：

  EP2325181B1
• 作为产物：
  描述：

  2-苯基-4-喹啉羧酸 在 吡啶 、 氯化亚砜 作用下， 反应 6.0h， 生成 STX-0119
  参考文献：
  名称：

  STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT

  摘要：

  公开号：

  EP2325181B1

文献信息

• ARYL BENZYLAMINE COMPOUNDS
  申请人：ANGST Daniela

  公开号：US20110190258A1

  公开（公告）日：2011-08-04

  The present invention relates to substituted aryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.

  本发明涉及取代芳基苄胺化合物，其生产过程，其作为药物的用途以及包含它们的药物组成物。
• STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient
  申请人：Asai Akira

  公开号：US08466290B2

  公开（公告）日：2013-06-18

  The present invention provides a STATS inhibitor containing as an active ingredient, a quinolinecarboxamide derivative represented by the formula (I) (in the formula, W represents a bond or an alkylene chain; X represents O, S, or NR34; and R1 to R8 and R34 each represent H, halogen, alkyl, phenyl, furyl, thienyl, or the like), or a pharmacologically acceptable salt thereof.

  本发明提供了一种STATS抑制剂，其含有一种以公式(I)表示的喹啉羧酰胺衍生物作为活性成分（在公式中，W表示键或烷基链；X表示O，S或NR34；R1至R8和R34各自表示H，卤素，烷基，苯基，呋喃基，噻吩基或类似物），或其药理学上可接受的盐。
• STAT3 INHIBITOR
  申请人：BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

  公开号：US20150361031A1

  公开（公告）日：2015-12-17

  Provided are STAT3 inhibitors and methods of treating inflammation or a hyperproliferative disease such as, e.g., cancer. In some aspects, compounds may be used to treat breast cancer, a head/neck cancer, a lung cancer, a prostate cancer, or pancreatic cancer.

  提供了STAT3抑制剂和治疗炎症或过度增殖疾病（例如癌症）的方法。在某些方面，化合物可用于治疗乳腺癌、头颈癌、肺癌、前列腺癌或胰腺癌。
• CANCER COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE
  申请人：Kabushiki Kaisha Yakult Honsha

  公开号：EP3854397A1

  公开（公告）日：2021-07-28

  Provided is a method for using a STAT3 inhibitor having a high antitumor effect and little side effects. The antitumor agent comprises a combination of a quinoline carboxamide derivative of formula (I) below or a pharmacologically acceptable salt thereof with one or more cancer molecular target drugs selected from the group consisting of an ALK inhibitor, an EGFR inhibitor, a multi kinase inhibitor, a HER2/EGFR inhibitor, an mTOR inhibitor, a BRAF inhibitor, a MEK inhibitor and a BCR-ABL inhibitor, wherein R1, R2, R3, R4, R5 and R6 are the same or different, and each represent a hydrogen atom, a substituted or unsubstituted aryl group, a substituted or unsubstituted aromatic heterocyclic group, COOR7 (wherein R7 represents a substituted or unsubstituted alkyl group), or OR8 (wherein R8 represents a substituted or unsubstituted alkyl group).

  本发明提供了一种使用 STAT3 抑制剂的方法，该抑制剂具有较高的抗肿瘤效果且副作用小。该抗肿瘤药包括下式(I)的喹啉羧酰胺衍生物或其药理学上可接受的盐与一种或多种选自由 ALK 抑制剂、表皮生长因子受体抑制剂、多激酶抑制剂、HER2/EGFR 抑制剂、mTOR 抑制剂、BRAF 抑制剂、MEK 抑制剂和 BCR-ABL 抑制剂组成的组的癌症分子靶向药物的组合、MEK抑制剂和BCR-ABL抑制剂，其中R1、R2、R3、R4、R5和R6相同或不同，各自代表氢原子、取代或未取代的芳基、取代或未取代的芳杂环基、COOR7（其中R7代表取代或未取代的烷基）或OR8（其中R8代表取代或未取代的烷基）。
• Identification of a New Series of STAT3 Inhibitors by Virtual Screening
  作者：Kenji Matsuno、Yoshiaki Masuda、Yutaka Uehara、Hiroshi Sato、Ayumu Muroya、Osamu Takahashi、Takane Yokotagawa、Toshio Furuya、Tadashi Okawara、Masami Otsuka、Naohisa Ogo、Tadashi Ashizawa、Chie Oshita、Sachiko Tai、Hidee Ishii、Yasuto Akiyama、Akira Asai

  DOI：10.1021/ml1000273

  日期：2010.11.11

  The signal transducer and activator of transcription 3 (STAT3) is considered to be an attractive therapeutic target for oncology drug development. We identified a N-[2-(1,3,4-oxadiazolyl)]-4-quinolinecarboxamide derivative, STX-0119, as a novel STAT3 dimerization inhibitor by a virtual screen using a customized version of the DOCK4 program with the crystal structure of STAT3 In addition, we used in vitro cell-based assays such as the luciferase reporter gene assay and the fluorescence resonance energy transfer-based STAT3 dimerization assay STX-0119 selectively abrogated the DNA binding activity of STAT3 and suppressed the expression of STAT3-regulated oncoproteins such as c-myc and survivin in cancer cells. In contrast a truncated inactive analogue, STX-0872, did not exhibit those activites, Oral administration of STX-0119 effectively abrogated the growth of human lymphoma cells in a SCC-3 subcutaneous xenograft model without visible toxicity Structure-activity relationships of STX-0119 derivatives were investigated using the docking model of the STAT3-SH2 domain/STX-0119.